Apixaban vs rivaroxaban for venous thromboembolism: a systematic review and meta-analysis
In brief
Apixaban linked to 28% less major bleeding than rivaroxaban for VTE
In a meta-analysis of 13 studies with more than 220,000 adults, apixaban was associated with 15% less recurrent venous thromboembolism and 28% less major bleeding than rivaroxaban; combined clinical harm was also lower. Mortality did not differ significantly, and because most evidence was observational, the findings show an association rather than proof that one drug is superior.
- Journal
- Internal and emergency medicine (Q1)
- Published
- 9 October 2026
- Study design
- Systematic review of cohort studies
- Evidence level
- Level 2, Moderate (CEBM 2a)
- Authors
- Bassel Alrabadi, Omar Alomari, Alwaleed Emad Alshakhshir, Shahad S Abdelwahab, Natalie Bandak
- PMID
- 42855613
- DOI
- 10.1007/s11739-026-04556-y
Why clinicians should know about it
- Picked for Internal Medicine (paper of the day, 11 October 2026): Apixaban shows lower recurrent VTE and major bleeding versus rivaroxaban
Abstract
Direct oral anticoagulants are first-line therapy for venous thromboembolism (VTE), yet comparative evidence between apixaban and rivaroxaban remains limited. This systematic review and meta-analysis aimed to compare the efficacy and safety of apixaban versus rivaroxaban in patients with VTE. A systematic search of PubMed, Scopus, Web of Science, and Cochrane Library was conducted from inception through March 2026. Studies directly comparing apixaban and rivaroxaban in adult VTE patients were included. Outcomes, including recurrent VTE, major bleeding, all-cause mortality, and net clinical harm, were pooled using a random-effects model. Thirteen studies comprising more than 220,000 patients were included. Apixaban was associated with a significantly lower risk of recurrent VTE compared to rivaroxaban (RR 0.85; 95% CI 0.74-0.98), with moderate heterogeneity. Apixaban was also associated with a significant 28% reduction in major bleeding risk (RR 0.72; 95% CI 0.65-0.81), with low heterogeneity, indicating consistent findings across studies. When efficacy and safety outcomes were combined, apixaban demonstrated a significantly lower risk of net clinical harm (RR 0.76; 95% CI 0.68-0.86). In contrast, no statistically significant difference was observed in all-cause mortality (RR 0.95; 95% CI 0.80-1.12), with substantial heterogeneity across studies. Sensitivity analyses confirmed the robustness of these findings, with no single study significantly altering the overall estimates. Overall, apixaban demonstrated a more favorable efficacy and safety profile compared with rivaroxaban in VTE management, with reduced recurrence and bleeding risk, while mortality remained comparable. These findings suggest that apixaban may be associated with a more favorable efficacy and safety profile than rivaroxaban; however, the results should be interpreted cautiously given the predominance of observational evidence.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.